stoxline Quote Chart Rank Option Currency Glossary
  
Theratechnologies Inc. (THTX)
1.66  0.18 (12.16%)    03-28 16:00
Open: 1.45
High: 1.66
Volume: 62,498
  
Pre. Close: 1.48
Low: 1.45
Market Cap: 76(M)
Technical analysis
2024-03-28 4:54:40 PM
Short term     
Mid term     
Targets 6-month :  1.98 1-year :  2.31
Resists First :  1.7 Second :  1.98
Pivot price 1.28
Supports First :  1.36 Second :  1.15
MAs MA(5) :  1.42 MA(20) :  1.31
MA(100) :  1.55 MA(250) :  2.23
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  90.1 D(3) :  73.3
RSI RSI(14): 67.1
52-week High :  4.32 Low :  0.87
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ THTX ] has closed Bollinger Bands are 6.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.66 - 1.67 1.67 - 1.67
Low: 1.44 - 1.44 1.44 - 1.45
Close: 1.65 - 1.66 1.66 - 1.67
Company Description

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Headline News

Wed, 27 Mar 2024
What is the Market's View on Theratechnologies Inc (THTX) Stock's Price and Volume Trends Wednesday? - InvestorsObserver

Fri, 22 Mar 2024
Theratechnologies shifts focus, phases down preclinical research By Investing.com - Investing.com

Thu, 21 Mar 2024
Theratechnologies Appoints Jordan Zwick to its Board of Directors - Yahoo Finance

Thu, 29 Feb 2024
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau - GlobeNewswire

Wed, 21 Feb 2024
Theratechnologies Inc. (THTX) Q4 2023 Earnings Call Transcript - Seeking Alpha

Wed, 07 Feb 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Theratechnologies Inc ... - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 46 (M)
Shares Float 34 (M)
Held by Insiders 6.2 (%)
Held by Institutions 50.8 (%)
Shares Short 27 (K)
Shares Short P.Month 21 (K)
Stock Financials
EPS -0.92
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.45
Profit Margin -29.3 %
Operating Margin 16.6 %
Return on Assets (ttm) -6.4 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 9.5 %
Gross Profit (p.s.) 0
Sales Per Share 1.77
EBITDA (p.s.) -0.13
Qtrly Earnings Growth 0 %
Operating Cash Flow -6 (M)
Levered Free Cash Flow -1 (M)
Stock Valuations
PE Ratio -1.83
PEG Ratio 0
Price to Book value -3.69
Price to Sales 0.93
Price to Cash Flow -13.44
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android